Table 1 Clinical characteristics of VA-ECMO patients on day 1

Patients, n (%)

14 (100)

Survivors, n (%)

7 (50)

Age, y (IQR)

71 (57–75)

Female, n (%)

5 (36)

Duration of ICU-stay (d, IQR)

12 (7–17)

VA-ECMO Device, n (%)

 Stöckert Sorin

9 (64)

 Maquet

5 (36)

Duration of ECMO (d, IQR)

7 (6–7)

ECMO Blood Flow (l/min, IQR)

4.3 (3.3–4.6)

Indication for VA-ECMO, n (%)

 Cardiogenic shock

  Postoperative

7 (50)

  Medical

7 (50)

    eCPR

3 (21)

Coronary Heart Disease, n (%)

9 (64)

Atrial fibrillation, n (%)

7 (50)

Diabetes mellitus, n (%)

1 (7)

Hypertension, n (%)

3 (21)

Active Smoker, n (%)

2 (14)

Hypercholesterolemia, n (%)

1 (7)

Cancer, n (%)

0 (0)

Acute renal failure, n (%)

10 (71)

Continuous hemodialysis, n (%)

6 (43)

 Major bleeding, n (%)

6 (43)

Intracerebral bleeding, n (%)

1 (7)

Minor bleeding, n (%)

4 (29)

Heparin, n (%)

13 (93)

Dual anti-platelet therapy, n (%)

6 (43)

Steroids, n (%)

1 (7)

Mechanical ventilation, n (%)

14 (100)

SOFA score (IQR)

11.0 (8.0–11.0)

Hb (g/dl, IQR)

8.5 (8.3–8.9)

Platelets (× 10³/µl, IQR)

109 (79–154)

Creatinine (mg/dl, IQR)

1.3 (1.0–2.5)

Urea (mg/dl, IQR)

51.0 (38.0–71.0)

Bilirubin (mg/dl, IQR)

2.2 (1.6–2.9)

AST (U/l, IQR)

157.0 (58.8–509.3)

ALT (U/l, IQR)

55.0 (21.8–123.8)

Lactate (mmol/l, IQR)

3.6 (1.5–5.3)

Leukocytes (× 10³/µl, IQR)

8.9 (6.9–11.2)

CRP (mg/l, IQR)

54.1 (24.5–90.6)

IL-6 (pg/ml, IQR)

370.5 (308.5–784.8)

p_aO₂ (mmHg, IQR)

111.0 (81.8–239.0)

p_aCO₂ (mmHg, IQR)

38.4 (35.3–50.0)

F_iO (%, IQR)

47.5 (40.0–50.0)

PEEP (mbar, IQR)

8.0 (7.0–10.0)

Respiratory rate (/min, IQR)

14.0 (11.0–18.0)